U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Liquidia Technologies (LQDA) PT Lowered to $29 at H.C. Wainwright
August 20, 2024 6:12 AM EDTH.C. Wainwright analyst Andrew S. Fein lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $29.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "Patent attorney's thoughts on competitor's patent exclusivity. From our conversations with a patent attorney, in terms of the patent exclusivity that was recently granted to Tyvasao, it is important to note that there are various types of exclusivity under the Hatch-Waxman Act. The New Chemical Entity (NCE) exclusivity ran out on Treprostinil five years after Remodulin was approved and only one NCE exclusivity is granted per... More
Liquidia Technologies (LQDA) PT Lowered to $23 at BofA Securities
August 20, 2024 4:56 AM EDTBofA Securities analyst Greg Harrison lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $23.00 (from $24.00) while maintaining a Buy rating.
The analyst comments "We update our LQDA PO to $23/shr (from $24) based on todays update the FDA will issue final Yutrepia... More
Liquidia Technologies (LQDA) PT Lowered to $17 at Jefferies
August 19, 2024 4:01 PM EDTJefferies analyst Kambiz Yazdi lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $17.00 (from $22.00) while maintaining a Buy rating.
The analyst comments "Tentative approval for Yutrepia in PAH and now PH-ILD was tempered by simultaneous grant of regulatory exclusivity for Tyvaso DPI until... More
Liquidia Technologies (LQDA) PT Lowered to $25 at BTIG
August 19, 2024 11:15 AM EDTBTIG analyst Julian Harrison lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $25.00 (from $29.00) while maintaining a Buy rating.
The analyst comments "Three-year New Clinical Investigation (NCI) Exclusivities are typically granted by the FDA soon after approval, making todays update unusual since Tyvaso DPI (UTHR, Neutral) has been approved since May 2022. 75% of... More
